Novartis Achieves Phase III Primary Endpoint with Fabhalta
Novartis, a leading innovative medicines company, has announced that its treatment Fabhalta (iptacopan) has met the primary endpoint in a Phase III trial, demonstrating its ability to slow kidney function decline in patients with IgA nephropathy (IgAN).
As a company, Novartis is dedicated to reimagining medicine to improve and extend people's lives, empowering patients, healthcare professionals, and societies in the face of serious disease. With its medicines reaching 296 million people worldwide, Novartis provides various resources for patients, caregivers, physicians, and healthcare professionals.
These resources include clinical trial recruiting, managed access programs, funding opportunities for patient organizations, and side effects reporting for patients and caregivers. For physicians and other healthcare professionals, Novartis offers clinical trial recruiting, grant funding, congresses, and country-level information.
Our goal is to reimagine medicine to improve and extend people's lives.
Commitment to Social Responsibility
Novartis is committed to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. The company's Integrated Report, "Novartis in Society", highlights its efforts to create a better future for all.
Author's summary: Novartis achieves milestone with Fabhalta treatment.